Skip to main content
Clinical Trials/IRCT20240117060720N1
IRCT20240117060720N1RecruitingPhase 2

Comparison of response to treatment and outcome between triple therapy (colistin + meropenem + ampicillin-sulbactam) and dual therapy (colistin + ampicillin-sulbactam) in patients with carbapenem-resistant Acinetobacter infection admitted to ICU; A randomized controlled trial

Gonabad University of Medical Sciences0 sites46 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Sponsor
Enrollment
46

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to no limit (—)
Sex
All

Inclusion Criteria

  • Consent of the patient (in case of unconsciousness, his/her companion) to conduct the study
  • ICU admission
  • Probable or definite infection with ventilator-associated pneumonia or hospital-acquired pneumonia or urosepsis or blood infection of any origin
  • Age 18 years or above
  • Report of Acinetobacter in the culture from the site of infection
  • Acinetobacter resistance to carbapenem

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Gonabad University of Medical Sciences

Similar Trials